Published in Cancer Vaccine Week, September 5th, 2005
Study 1: Researchers review new developments in dendritic cell-based vaccinations in a recent issue of Cancer Immunology Immunotherapy.
According to a study from Germany, "Dendritic cells (DCs) are the most powerful antigen-presenting cells that induce and maintain primary immune responses in vitro and in vivo. The development of protocols for the ex vivo generation of DCs provided a rationale for designing and developing DC-based vaccination studies for the treatment of infectious and malignant diseases.
"Recently, it was shown...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.